Holen Sie sich die Stockscreener-App
78.24
2.13%
1.63
Handel nachbörslich:
78.24
Schlusskurs vom Vortag:
$76.61
Offen:
$77.43
24-Stunden-Volumen:
269.01K
Relative Volume:
0.54
Marktkapitalisierung:
$5.22B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-20.06
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
+1.31%
1M Leistung:
-3.32%
6M Leistung:
-3.35%
1J Leistung:
+9.52%
1-Tages-Spanne:
$76.55
$79.00
1-Wochen-Bereich:
$71.13
$79.00
52-Wochen-Spanne:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
78.24 | 5.40B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Nuvalent to present pivotal lung cancer drug data at WCLC 2025 By Investing.com - Investing.com South Africa
Nuvalent to present pivotal lung cancer drug data at WCLC 2025 - Investing.com Australia
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium - PR Newswire
Regression Model Predicts Rangebound Movement in Nuvalent Inc.Low Risk High Return Opportunities Identified - 선데이타임즈
J.P. Morgan Analyst Keeps Buy Rating on Nuvalent with $111 Price Target - AInvest
How Nuvalent Inc. stock performs during market volatilityTop Fast Growth Opportunities - thegnnews.com
Can Nuvalent Inc. navigate macro headwindsWeekly Investment Watchlist - sisain.net
Nuvalent Reports Q2 2025 Financials and Pipeline Progress - TipRanks
Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating - TipRanks
Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating - TipRanks
Nuvalent's Q2 Net Loss Widens - MarketScreener
Nuvalent's 2025 Momentum: Catalysts, Commercial Readiness, and Cash Runway Positioning for a Breakout Year - AInvest
Nuvalent (NUVL) Q2 R&D Up 65% - The Motley Fool
Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug By Investing.com - Investing.com Australia
Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug - Investing.com India
Earnings Flash (NUVL) Nuvalent Posts Q2 Net Loss Per Share $1.39, vs. FactSet Est of $1.22 - MarketScreener
Nuvalent, Inc. SEC 10-Q Report - TradingView
Nuvalent's Dual Victory: FDA Rolling Review for ROS1 Cancer Drug While Phase 3 Trial Advances New ALK Treatment - Stock Titan
Analysts' Bullish Sentiments on Healthcare Companies: Avantor, Nuvalent, and Alphatec Holdings - AInvest
What catalysts could drive Nuvalent Inc. stock higher in 2025Build wealth faster with consistent growth stocks - Jammu Links News
What makes Nuvalent Inc. stock price move sharplyInvest confidently with professional market insights - Jammu Links News
Is Nuvalent Inc. a growth stock or a value stockExceptional financial outcomes - Jammu Links News
How volatile is Nuvalent Inc. stock compared to the marketInvest confidently with real-time data - Jammu Links News
What is the dividend policy of Nuvalent Inc. stockDynamic investment growth - Jammu Links News
How many analysts rate Nuvalent Inc. as a “Buy”Achieve breakthrough investment performance - Jammu Links News
What institutional investors are buying Nuvalent Inc. stockFind the best stocks for sustainable growth - Jammu Links News
What is the risk reward ratio of investing in Nuvalent Inc. stockGet ahead with breakthrough trading ideas - Jammu Links News
Published on: 2025-08-03 06:27:04 - Jammu Links News
Nuvalent’s Noci sells $321k in shares By Investing.com - Investing.com Australia
Nuvalent’s Noci sells $321k in shares - Investing.com India
Why is Nuvalent Inc. stock attracting strong analyst attentionBest Dividend Report From AI Tools - Jammu Links News
Nuvalent Inc. stock outlook for YEARTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Will Nuvalent Inc. Stock Benefit from AI and Green Energy TrendsFast Return Equity Trade Forecast Points to Small Caps - metal.it
Nuvalent Inc. Moves Into Overbought Range Analysts CautiousDay Trading Signals With High Precision Reviewed - metal.it
How high can Nuvalent Inc. stock price go in 2025AI Screening for Swing Trade Picks Finds Momentum - metal.it
Can Traders Expect Breakout From Nuvalent Inc. This WeekSmart Trade Plans With Risk Protection Explained - metal.it
Should I hold or sell Nuvalent Inc. stock in 2025Capitalize on market momentum for maximum gains - Jammu Links News
How does Nuvalent Inc. compare to its industry peersAchieve breakthrough profits with smart strategies - Jammu Links News
Nuvalent Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingHigh Return Potential - metal.it
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvalent Inc-Aktie (NUVL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pelish Henry E. | Chief Scientific Officer |
Aug 07 '25 |
Sale |
74.85 |
5,500 |
411,675 |
60,956 |
| Noci Darlene | Chief Development Officer |
Jul 30 '25 |
Option Exercise |
27.85 |
4,000 |
111,400 |
52,034 |
| Noci Darlene | Chief Development Officer |
Jul 30 '25 |
Sale |
80.36 |
4,000 |
321,440 |
48,034 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):